US2004247562A1PendingUtilityA1

Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3

Priority: Sep 28, 2001Filed: Jan 18, 2002Published: Dec 9, 2004
Est. expirySep 28, 2021(expired)· nominal 20-yr term from priority
C07K 16/243C12N 15/11C12Q 2600/156C12Q 1/6886
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.

Claims

exact text as granted — not AI-modified
1 . A mutated G-CSF mRNA or cDNA fragment having a deletion of an exon 3 region for use as a diagnostic cancer marker.  
     
     
         2 . A mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region for use as a diagnostic cancer marker.  
     
     
         3 . A microarray for diagnosis of cancer comprising (a) a DNA fragment corresponding to exon 3 of a G-CSF gene, and (b) at least one of DNA fragments corresponding to exons 1, 2, 4 and 5 of said G-CSF gene are bound.  
     
     
         4 . A diagnostic agent for cancer comprising an antibody against a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region of said G-CSF protein.  
     
     
         5 . A diagnostic kit for cancer comprising an antibody against a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region of said G-CSF protein.  
     
     
         6 . A microarray for diagnosis of cancer comprising an antibody against a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region of said G-CSF protein.  
     
     
         7 . (Cancelled)  
     
     
         8 . A primer for use in amplification of a G-CSF gene in a G-CSF nucleic acid sample obtained from mammalian tissues or cells, wherein said primer is selected from the group consisting of the following nucleotide sequence pairs:  
       
         
           
                 
                 
                 
                 
               
                     
                     
                 
                     
                   sense: 
                     
                     
                 
                     
                   5′-ACCCCCCTGGGCCCTGCC-3′ 
                   (SEQ ID NO. 1) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-TCAGGGCTGGGCAAGGTG-3′; 
                   (SEQ ID NO. 2) 
                 
                     
                     
                 
                     
                   sense: 
                 
                     
                   5′-ACCCCCCTGGGCCCTGCC-3′ 
                   (SEQ ID NO. 1) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-CAGCTGCAGGGCCTGGCT-3′; 
                   (SEQ ID NO. 5) 
                 
                     
                     
                 
                     
                   sense: 
                 
                     
                   5′-ACCCCCCTGGGCCCTGCC-3′ 
                   (SEQ ID NO. 1) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-CGCTATGGAGTTGGCTCAAGC-3′; 
                   (SEQ ID NO. 6) 
                 
                     
                     
                 
                     
                   sense: 
                 
                     
                   5′-ACCCCCCTGGGCCCTGCC-3′ 
                   (SEQ ID NO. 1) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-CAGCTTCTCCTGGAGCGC-3′; 
                   (SEQ ID NO. 9) 
                 
                     
                     
                 
                     
                   sense: 
                 
                     
                   5′-ATCCAGGGCGATGGCGCAGCG-3′ 
                   (SEQ ID NO. 3) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-TCAGGGCTGGGCAAGGTG-3′; 
                   (SEQ ID NO. 2) 
                 
                     
                     
                 
                     
                   sense: 
                 
                     
                   5′-ATCCAGGGCGATGGCGCAGCG-3′ 
                   (SEQ ID NO. 3) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-CAGCTGCAGGGCCTGGCT-3′; 
                   (SEQ ID NO. 5) 
                 
                     
                     
                 
                     
                   sense: 
                 
                     
                   5′-ATCCAGGGCGATGGCGCAGCG-3′ 
                   (SEQ ID NO. 3) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-CGCTATGGAGTTGGCTCAAGC-3′; 
                   (SEQ ID NO. 6) 
                 
                     
                     
                 
                     
                   sense: 
                 
                     
                   5′-TGTGCCACCTACAAGCTGTGC-3′ 
                   (SEQ ID NO. 4) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-TCAGGGCTGGGCAAGGTG-3′; 
                   (SEQ ID NO. 2) 
                 
                     
                     
                 
                     
                   sense: 
                 
                     
                   5′-TGTGCCACCTACAAGCTGTGC-3′ 
                   (SEQ ID NO. 4) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-CAGCTGCAGGGCCTGGCT-3′; 
                   (SEQ ID NO. 5) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   sense: 
                 
                     
                   5′-TGTGCCACCTACAAGCTGTGC-3′ 
                   (SEQ ID NO. 4) 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   antisense: 
                 
                     
                   5′-CGCTATGGAGTTGGCTCAAGC-3′. 
                   (SEQ ID NO. 6) 
                 
                     
                     
                 
             
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         9 . A mutated G-CSF protein having a deletion of an amino acid sequence corresponding to an exon 3 region.  
     
     
         10 . An antibody specifically binding to the mutated G-CSF protein of  claim 9 .  
     
     
         11 . The antibody as set forth in  claim 10 , wherein the antibody is a polyclonal antibody.  
     
     
         12 . The antibody as set forth in  claim 10 , wherein the antibody is a monoclonal antibody.

Join the waitlist — get patent alerts

Track US2004247562A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.